Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Abstract Background The World Health Organization recommends 2 doses of human papillomavirus (HPV) vaccine for adults without human immunodeficiency virus (HIV) but 3 doses in persons with HIV. There are no immunogenicity data on the 2-dose schedule in women with HIV (WWH). Methods This was a prospective study comparing 2 doses (months 0 and 6) versus 3 (months 0, 2, and 6) doses of 9-valent vaccine (Gardasil 9, Merck Sharp & Dohme) in WWH (15–40 years), on antiretrovirals with HIV RNA <400 copies/mL, enrolled during 2018–2021. After an open-label phase assessing safety (n = 45 receiving 3 doses), participants were randomized between 2 or 3 doses. Primary outcome was noninferiority of 2 doses compared to 3 doses for seroconversion against all vaccine genotypes. Due to the COVID-19 pandemic, 100 WWH, instead of initially planned 120, were randomized. The trial was further amended to give 2 doses to all participants enrolled thereafter (n = 22). Results were analyzed in modified intention-to-treat (mITT) on the randomized cohort (n = 100) and per protocol on the whole cohort (n = 167). Results Participants’ median age was 35 years, median CD4 count was 649 cells/µL, and 16 missed the month 7 visit. In mITT, seroconversion was 97.7% for 2 doses and 97.9% for 3 doses, meeting the predefined noninferiority criteria. At month 7, antibodies titers against all vaccine genotypes were high in both groups (increase by 1.2–2.4 log10). There were no serious adverse events; participants with 3 doses experienced local reactions more frequently (82% vs 60% for 2 doses, P = .027) with more symptoms and longer duration. Conclusions In women with well-controlled HIV, 2 doses of 9-valent HPV vaccine is noninferior to 3 doses in terms of seroconversion and is associated with less reactogenicity. Clinical Trials Registration NCT03391921; EUDRACT 2018-000228-33; CTIS-EMA 2024-520419-42-00.
Physical review letters · 2026
Anisotropic flow and radial flow are two key probes of the expansion dynamics and properties of the quark-gluon plasma (QGP). While anisotropic flow has been extensively studied, radial flow, which governs the system’s radial expansion, has received less attention. Notably, direct experimental evidence for the global and collective nature of radial flow fluctuations has been lacking. This Letter presents the first measurement of transverse momentum ( p T ) dependence of radial flow fluctuations ( v 0 ( p T ) ) over 0.5 < p T < 10 GeV and demonstrates its collective nature using a two-particle correlation method in Pb + Pb collisions at s NN = 5.02 TeV . The data reveal three key features supporting the collective nature of radial flow: long-range correlation in pseudorapidity, factorization in p T , and centrality-independent shape in p T . The comparison with a hydrodynamic model demonstrates the sensitivity of v 0 ( p T ) to bulk viscosity, a crucial transport property of the QGP. These findings establish a new, powerful tool for probing collective dynamics and properties of the QGP.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Emerging microbes & infections · 2026 · Journal Article
Wesselmann K, Luciani L, Moureau G, Driouich JS, et al.
Australian and New Zealand journal of public health · 2026 · Journal Article
Dean M, Moore HC, Richardson A, Slota-Kan S, et al.
Journal of cellular and molecular medicine · 2026 · Journal Article
G P, Shivhare K, Gupta PK, Sahebkar A, et al.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026 · Journal Article
Moyaert J, Uwents MH, Van de Heyning P, Gilles A, et al.
The Journal of frailty & aging · 2026 · Journal Article
Gilles V, Flaus A, Teillac A, Verny M, et al.
Gastro hep advances · 2026 · Journal Article
Ioannou GN, Yakovchenko V, Taddei T, Monto A, et al.
Infectious diseases now · 2025 · Journal Article
Carvelli J, Mortier C, Boucekine M, Gilles V, et al.
Journal of medical Internet research · 2025 · Journal Article
Burchim S, Miller S, Beima-Sofie K, Spencer AG, et al.
Bioinformation · 2025 · Journal Article
G N, M SSL, V S, K S, et al.
Cureus · 2025 · Journal Article
Tk A, Veluguleti U, Sheenam N, G S, et al.
Frontiers in neuroscience · 2026 · Journal Article
Biot L, Cardon E, Jacxsens L, Gilles A, et al.
Journal of medical Internet research · 2026 · Journal Article
Demoen S, Van Kerchove E, Timmermans A, Van Rompaey V, et al.
Physical review letters · 2026 · Journal Article
Aad G, Aakvaag E, Abbott B, Abdelhameed S, et al.
Physical review letters · 2025 · Journal Article
Aad G, Aakvaag E, Abbott B, Abdelhameed S, et al.
Frontiers in neuroscience · 2026 · Journal Article
Biot L, Cardon E, Jacxsens L, Gilles A, et al.
Journal of medical Internet research · 2026 · Journal Article
Demoen S, Van Kerchove E, Timmermans A, Van Rompaey V, et al.
The Journal of allergy and clinical immunology · 2026 · Journal Article
Maier L, Sun Y, Kronberg J, Abner E, et al.
Clinical nutrition ESPEN · 2025 · Journal Article
J N H, G G, Mahadevan S, R I
Nature medicine · 2026 · Journal Article
Menozzi E, Ren Y, Geiger M, Macnaughtan J, et al.
Microbiology spectrum · 2025 · Journal Article
Plaza Oñate F, Quinquis B, Thirion F, Gilles M, et al.
Frontiers in neuroscience · 2025 · Journal Article
Menozzi E, Geiger M, Meslier V, Fierli F, et al.
Kidney international · 2026 · Journal Article
Wang X, Jiang L, Nanayakkara K, Sun X, et al.
Journal of medical Internet research · 2026 · Journal Article
Demoen S, Van Kerchove E, Timmermans A, Van Rompaey V, et al.
Case reports in endocrinology · 2025 · Case Reports
D K, Moradeyo AY, G B
Infectious diseases now · 2025 · Journal Article
Atoun RC, Youa IF, Bawe LD, Tchaou I, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · Journal Article
Konopnicki D, Gilles C, Manigart Y, Barlow P, et al.
The Journal of allergy and clinical immunology · 2026 · Journal Article
Maier L, Sun Y, Kronberg J, Abner E, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · Journal Article
Konopnicki D, Gilles C, Manigart Y, Barlow P, et al.
Ear and hearing · 2025 · Journal Article
Jorissen C, Moyaert J, Dobbels B, Van de Heyning P, et al.
Clinical nutrition ESPEN · 2025 · Journal Article
J N H, G G, Mahadevan S, R I
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025 · Journal Article
Wagenaar O, Gilles A, Jacquemin L, Van Rompaey V, et al.
Physical review letters · 2025 · Journal Article
Aad G, Aakvaag E, Abbott B, Abdelhameed S, et al.